Novel potent benzimidazole-based microsomal prostaglandin E-2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C-4 synthase

Ergul A. G., GÜR MAZ Z. T., Kretzer C., OLĞAÇ A., Jordan P. M., ÇALIŞKAN B., ...More

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.231, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 231
  • Publication Date: 2022
  • Doi Number: 10.1016/j.ejmech.2022.114167
  • Journal Name: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, MEDLINE, Veterinary Science Database, Index Chemicus (IC)
  • Keywords: mPGES-1, Leukotriene, Benzimidazole, Oxadiazolethione, Benzyloxy, PGE(2), ACCURATE DOCKING, BIOSYNTHESIS, 5-LIPOXYGENASE, IDENTIFICATION, INFLAMMATION, DERIVATIVES, THERAPY, DESIGN, GLIDE, ACIDS
  • Lokman Hekim University Affiliated: Yes

Abstract

Microsomal prostaglandin E-2 synthase-1 (mPGES-1) is recognized as a promising therapeutic target for next-generation anti-inflammatory drugs to treat inflammatory diseases. In this study, we report the identification of new, potent and selective inhibitors of human mPGES-1 such as compounds 10, 31 and 49 with IC50 of 0.03-0.09 mM in a cell-free assay of PGE(2) production. Compound 10 and 49 also inhibited leukotriene C-4 synthase (LTC4S) at sub-mM concentrations (IC50 = 0.7 and 0.4 mM, respectively), affording compounds dually targeting inflammatory PGE(2) and cysteinyl leukotriene (cys-LT) biosynthesis. However, compound 31 showed substantial selectivity towards mPGES-1 (IC50 = 0.03 mM) with a decreased inhibitory activity on LTC4S (IC50 = 2.8 mM), and also on other related targets such as FLAP and 5-LO. These oxadiazole thione-benzimidazole derivatives warrant further exploration of new and alternative analogs that may lead to the identification of novel derivatives with potent anti-inflammatory properties.& nbsp;(c) 2022 Elsevier Masson SAS. All rights reserved.